To include your compound in the COVID-19 Resource Center, submit it here.

Genentech's alternative to breakthrough committee

WASHINGTON - Genentech Inc. last week proposed to members of Congress that the Clinton administration's breakthrough drugs committee be abandoned in favor of technology assessment activities that would do a better job of accommodating the funding and development of improved medical technologies.

At a hearing of the House subcommittee on technology, environment and

Read the full 520 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers